Page 171 - Haematologica Vol. 107 - September 2022

ARTICLE - Immune deficiency during RM after transplantation L. Bouard et al.
Table 3. Univariate analysis for infectious episode, neutropenia, hypogammaglobulinemia and CD4 lymphopenia.
Infectious episode (%)
Neutropenia (%)
Hypogamma- globulinemia < 6X109/L(%)
CD4 lymphopenia (%)
Sex
Male N=189 Female N=51
32.3 41.2
0.25
11.1 9.8
1.0
78.8 82.4
0.70
21.2 17.6
0.70
Age
<60 y N=172 >60 y N=68
34.9 32.4
0.76
8.7 16.2
0.11
78.5 82.4
0.60
22.7 14.7
0.21
PS
0 N=156 1 N=74 2 N=10
35.9 33.8 10.0
0.27
9.6 13.5 10.0
0.60
81.4 77.0 70.0
0.47
16.0 31.1 10.0
0.02
Ann arbor II N=12
III N=31 IV N=196
50.0 25.8 34.2
0.30
8.3
9.7 11.2
1.0
100 77.4 78.6
0.22
8.3 25.8 20.4
0.49
MIPI score Low N=133 Int N=65 High N=42
33.8 41.5 23.8
0.17
9.8 12.3 11.9
0.81
80.5 73.8 85.7
0.33
21.1 18.5 21.4
0.91
Morphologic variant Classic N=134 Others N=36
31.3 33.3
0.84
8.2 13.9
0.34
76.1 88.9
0.11
20.1 25.0
0.50
Bone marrow involvement Yes N=149
No N=72
36.2 27.8
0.46
12.8 6.9
0.44
79.9 79.2
0.90
20.8 19.4
0.87
PS post R-DHAC 0 N=163
1 N=67
2 N=4
32.5 34.3 25.0
0.95
14.1 4.5 0.0
0.11
78.5 80.6 100
0.83
19.6 23.9 25.0
0.63
PET post R-DHAC Pos. N=51
Neg. N=175
37.3 35.4
0.87
9.8 11.4
1.0
80.4 78.9
1.0
23.5 18.9
0.55
Medullar response post R-DHAC Yes N=179
No N=5
33.0 0.0
0.18
10.1 20.0
0.42
78.8 100
0.59
21.2 0.0
0.59
CT scanner post R-DHAC Cr N=115
Pr>75% N=97
Pr<75% N=22
33.0 33.0 45.5
0.51
10.4 11.3 9.1
0.95
83.5 73.2 90.0
0.07
18.3 22.7 27.3
0.52
RCHOP salvage Yes N=11
No N=229
36.4 34.1
1.0
18.2 10.5
0.34
100 78.6
0.13
18.2 20.5
1.0
Asct-maintenance delay <=2 mth N=91
>2 mth N=149
38.5 31.5
0.33
12.1 10.1
0.67
82.4 77.9
0.42
23.1 18.8
0.51
Number of CD 34/kg <5.106 N=73 5-8.106 N=76 >8.106 N=90
35.6 26.3 40.0
0.17
8.2 14.5 8.9
0.42
78.1 84.2 76.7
0.45
17.8 21.1 21.1
0.86
Number of RM injections (in RM group only) <=9 inj N=23
>9 inj N=97
8.7 51.5
<.001
11.9 9.3
0.67
69.6 90.7
0.014
19.6 21.6
0.75
PS: performance status; PET: positron emission tomography; CT: computerized tomography; inj: injections; R-DHAC: rituximab, dexamethasone, cytarabine and platinum derivative; RCHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone; RM: rituximab mainten- ance; ASCT: autologous stem cell transplantation; MIPI: mantle cell lymphoma international prognostic index; mth: months.
Haematologica | 107 September 2022
2170